MedTrace Logo

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

NCT02782351 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-08-04

No results posted yet for this study

Summary

The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a humanized scFv. All participants will receive autologous chimeric antigen receptor engineered T cells.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

BIOLOGICAL

CAR-T

Patients will be infused with autologous CAR-T infusion in a dose escalating manner.

Sponsors & Collaborators

  • iCarTAB BioMed Inc.

    collaborator UNKNOWN

  • Huaian first people's hospital

    collaborator UNKNOWN

  • Kai Lin Xu; Jun Nian Zheng

    lead OTHER

Principal Investigators

  • KaiLin Xu, MD. Ph.D. · Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02782351 on ClinicalTrials.gov